IL-1 is a key inflammatory and immune mediator in many diseases, including dry-eye disease, and its inhibition is clinically efficacious in rheumatoid arthritis and cryopyrin-associated periodic syndromes. To treat ocular surface disease with a topical biotherapeutic, the uniqueness of the site necessitates consideration of the agent's size, target location, binding kinetics, and thermal stability. Here we chimerized two IL-1 receptor ligands, IL-1β and IL-1Ra, to create an optimized receptor antagonist, EBI-005, for topical ocular administration. EBI-005 binds its target, IL-1R1, 85-fold more tightly than IL-1Ra, and this increase translates to an ∼100-fold increase in potency in vivo. EBI-005 preserves the affinity bias of IL-1Ra for IL-1R1 over the decoy receptor (IL-1R2), and, surprisingly, is also more thermally stable than either parental molecule. This rationally designed antagonist represents a unique approach to therapeutic design that can potentially be exploited for other β-trefoil family proteins in the IL-1 and FGF families.
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T he IL-1 cytokines (IL-1α and IL-1β) are master mediators of inflammatory responses (1) . IL-1β also regulates immune function through its role in T helper 17 (Th17) cell differentiation and maintenance (2, 3) . IL-1 action has been implicated in numerous human diseases, including rheumatoid arthritis, MuckleWells syndrome, gout, type 2 diabetes, and stroke (4) . Several natural mechanisms directly oppose the actions of IL-1, including a soluble and cell surface decoy receptor (IL-1R2), a natural antagonist (IL-1Ra), and a soluble signaling receptor (IL-1R1) (5) . Therapeutics that block IL-1 based on these mechanisms have been developed (6) (7) (8) .
Recently, a nonoptimized formulation of anakinra (methionyl-IL-1Ra; Kineret) was shown to provide clinical benefit in dry-eye disease (DED) (9) . Moderate to severe DED is a chronic inflammatory condition of the corneal surface that results in pain, discomfort, and epitheliopathy (as measured by fluorescein staining). Inability to maintain a proper tear film over the cornea (owing to a variety of etiologies) results in desiccating stress, which drives an inflammatory cascade (10, 11) . IL-1 plays a central role in the initiation and maintenance of this cascade, as well as in the pain mediated by the corneal neural plexus. IL-1α and IL-1β protein are elevated in the lacrimal gland, tears, and the ocular surface in all forms of dry-eye disease (12) , and their mRNA is increased in both humans and in rodent disease models (13, 14) . Genetic ablation of IL-1R1, the primary receptor for IL-1α and IL-1β, can block the development of corneal staining in a Sjögren syndrome corneal epitheliopathy model (15) , and topically administered anakinra can improve surface epithliopathy in a mouse dry-eye model (14) . IL-1β is essential for Th17 cell differentiation and maintenance, and Th17 cells are likely the main effector cells that induce epithelial damage (2, 3) . Genetic and pharmacologic studies have shown that IL-1β mediates, and IL-1Ra blocks, normal, inflammatory, and neuropathic pain sensations (16) (17) (18) (19) .
The development of a topical biotherapeutic agent for DED presents a protein engineering challenge, requiring optimization for the biology and topical route of administration. Given the rapid turnover of tear volume (10% min −1 ) (20) , blocking the tissue-associated receptor would be preferred over blocking tearassociated ligands, and the agent's target affinity should be maximized to minimize clearance and the frequency of dosing. Considering the corneal epithelial barrier, smaller molecules would be preferable, and ideally the agent would have sufficient thermal stability to allow a room temperature formulation, to optimize patient compliance. We considered two designs for small, receptor-targeted agents: improved versions of IL-1Ra (∼17 kDa) and small-format (e.g., single-chain variable fragment) anti-IL-1R1 antibodies. Both designs can be expressed in Escherichia coli, but given the straightforward isolation of anakinra as a soluble protein after E. coli expression, and the fact that the existing clinical data are from the use of anakinra, we focused on improved receptor antagonists. Here we describe the creation of a unique type of chimeric molecule that meets the foregoing criteria.
Results
Creating IL-1β/IL-1Ra Chimeras. IL-1β and IL-1Ra engage the same primary receptor, IL-1R1, but only IL-1β recruits IL-1RAcP and signals (21) . Mutagenesis and structural studies have identified two disparate sites on IL-1β that participate in IL-1R1 binding, designated sites A and B, only one of which-site A-is formed with IL-1Ra (22) (23) (24) . Site A of the ligand binds to the first two Ig domains, D1 and D2, whereas site B binds to the third Ig domain, D3 (23, 24) (Fig. 1A) . Direct measurement of IL-1β and IL-1Ra affinity to D1 and D2 at the cell surface has shown that the affinity of site A of IL-1Ra is >300-fold greater than that of IL-1β (23) , whereas the affinity of site B of IL-1Ra is >200-fold lower (Table  S1 ). Thus, tighter binding might be created by combining site A from IL-1Ra and site B from IL-1β. This idea prompted us to design a series of chimeras that preserve these contacts (Fig. 1B) . Each of these chimeras is discontinuous with respect to the parental sequence, but on folding creates a continuous surface derived from one or the other parental molecule. The chimeras differ only in the "plane" used to bisect the structures. Whether the chimeras would be agonists or antagonists is not clear; the presence of site B has been presumed to be related to agonism, yet IL-1β contacts IL-1RAcP, which is required for signaling, in another site (25, 26) .
Expression and Activity. Each of the chimeras was expressed as a 6xHis-tagged soluble cytoplasmic protein in E. coli. We subsequently determined that untagged 93:60 was soluble in PBS to at least 115 mg/mL; however, two chimeras (39:113 and 54:98) predominantly formed inclusion bodies. One chimera (121:30) was a full agonist, one (100:53) was a weak agonist, and the other five were all antagonists (Fig. 1 C-H) , suggesting that site B is unrelated to agonism and IL-1RAcP recruitment. Chimera 121:30 appeared to be an even more potent agonist than IL-1β, whereas four of the five antagonists were of equal or greater potency than IL-1Ra.
The affinity of 121:30 for IL-1R1, as measured by surface plasmon resonance (SPR), was eightfold higher than that of IL-1β (Table 1) , resulting in a twofold to fourfold decrease in the EC 50 in two of three cell-based assays, while retaining full efficacy (Fig. 1  C-E) . The weak agonist, 100:53, had a 50-fold loss of affinity for IL-1R1 compared with IL-1β (Table 1) , but a 100-fold lower association rate constant, which was also seen for 39:113, 54:98, and 87:66. These four chimeras do not share any unique primary sequence features, suggesting that the lower association rate constants may derive from suboptimal folding. The reduced EC 50 of 100:53 (3.5-4.5 logs) was substantially greater than the reduced affinity, presumably owing to the substitution of key residues important for IL-1RAcP recruitment near D145 (Fig. S1 ) (26, 27) .
Among the antagonists, 93:60 had a much greater affinity for IL-1R1 than for IL-1Ra, and its IC 50 was the lowest of any of the antagonists in three different cell-based assays ( Fig. 1 F-H) . Because of a low dissociation rate constant, Its K D could not be measured accurately by SPR, so we directly measured the dissociation of His-tagged ligands from IL-1R1 in a competition assay (Fig. 1I) For a potential therapeutic chimera of an agonist and antagonist, it was important to establish that no agonist activity remained in the molecule. Chimera 93:60 exhibited no agonism in a cellbased assay, even at doses 10 7 higher than the IL-1β EC 50 (Fig. 1J) . Overall, the increase in affinity for both agonists and antagonists suggests that the combination of the higher affinity "poles" can indeed create more potent molecules.
Chimera Structure. To validate our design strategy, we performed a crystallographic analysis of our chimeras both free and in complex with IL-1R1. We determined the crystal structures of 93:60 (without a His tag) as well as the 93:60/IL-1R1 complex to 1.47 Å and 2.15 Å resolution, respectively (Table S2 and Fig. S3 ). These structures show that the chimeric segments of 93:60 fold remarkably like those regions in each of the parent molecules ( Fig.  2A) (23, 24) , with an rmsd of 0.65 Å for the α-carbon backbone between the actual chimera and a model chimera based on IL-1β and IL-1Ra coordinates. As with IL-1β and IL-1Ra, binding the ligand produces little change in the structure of 93:60, with Cα rmsd values between free and bound ligands of 1.76 Å (24), 0.8 Å (23), and 0.77 Å, respectively. Of note, sites A and B are fully engaged in the co-crystal structure, demonstrating that 93:60 adopts a canonical interaction with its receptor (Fig. 2B) . As a result, the total surface area buried at the 93:60/IL-1R1 interface is greater than that of either parent complexed to IL-1R1, by 178.2 Å 2 vs. IL-1β and 338.4 Å 2 vs. IL-1Ra (Table S3 ). The surface area of the IL-1R1 D1-D2 interface (site A) buried in the 93:60 complex is comparable to that in the IL-1Ra complex (1,141.8
, and hydrogen-bonded contacts and van der Waals interactions, including key affinity determinants, are preserved (Fig. 2C) . Similarly, site B interactions are fully preserved compared with those with IL-β and are reflected in the buried surface area at the IL-1R1 D3 interface (891.2 Å 2 vs. 880.5 Å 2 ) (Table S3 and Fig. 2D ). Acute Thermal Stability. To identify the most thermally stable antagonist, we determined melting temperature (T m ) values of the noninclusion body-forming chimeras and the 121:30 agonist vs. parental molecules using differential scanning fluorimetry (28) (Fig. 3A) . Whereas the T m values of IL-1Ra and IL-1β were below 60°C, all of the tested chimeras had a T m above 60°C, ranging up to 66°C (or 10°C higher than IL-1Ra) for 74:79 (Fig. 3B) . In addition, the most stable chimeras (93:60 and 74:79) unfolded over a narrower temperature range than the parental molecules, resulting in an even greater difference in the onset of unfolding (14-21.5°C higher) (Fig. 3B) .
This finding suggests that IL-1Ra and IL-1β have discrete thermally stable regions located at opposite "poles" that had been combined in the chimeras. If this were true, then an "inverse" 93:60, in which the alternative parental residue is present at each position compared with 93:60 (Fig. 3C and Fig. S1 ), should be less stable than either parental molecule. Strikingly, 60:91 was substantially less stable and precipitated at room temperature in PBS, with a 36°C lower T m and a 35°C lower temperature at onset of unfolding (T onset ) compared with 93:60 (Fig. 3 D and E) . Thus, it appears that in IL-1Ra, site A is far more thermally stable than site B, whereas the converse is true for IL-1β.
IL-1R1 vs. IL-1R2 Binding. The decoy receptor IL-1R2 does not signal, but has a much greater affinity for IL-1β compared with IL-1Ra, especially when shed from the cell surface (29) (30) (31) . To characterize the chimeras with respect to IL-1R2 binding, we determined their K D values by SPR ( Table 2 ). The K D of IL-1β was more than fourfold lower for IL-1R2 than for IL-1R1, marked by a much lower dissociation rate constant, but was 300-fold higher for IL-1Ra, marked by a much higher dissociation rate constant. These values are consistent with those published previously (30) . The IL-1R2/IL-1R1 K D ratios for most of the chimeras (particularly the agonist 121:30) were substantially greater than 1, suggesting that the receptor selectivity is analogous to that of IL-1Ra. The tightest-binding chimera was 93:60, although it was still 5,300-fold more selective for IL-1R1 compared with IL-1R2. Although 93:60 bound approximately fourfold more tightly to IL-1R2 than did IL-1Ra (suggesting a contribution from site B), it still bound >20-fold more weakly than IL-1β. Chimera 100:53, the weakest IL-1R1 binder, did not bind IL-1R2 up to 200 nM.
Potency in Vivo. The foregoing analyses suggested that 93:60 had the most suitable properties among the chimeras, and thus this chimera was chosen for in vivo analysis. In a therapeutic animal model of DED in which corneal surface damage (as measured by corneal fluorescein staining) is first induced in a constant low humidity (20% relative humidity) environment before application of drugs, topical application of 50 mg/mL anakinra three times daily has been associated with decreased corneal fluorescein staining, number of infiltrating CD11 + cells, IL-1β expression, and lymphatic ingrowth (14) . We were interested in testing 93:60 for less frequent dosing compared with anakinra and in determining the lower limit of effective concentrations. At 10 mg/mL and twice-daily administration, topical therapy with anakinra achieved significant reduction (mean staining score, 8.5 vs. 10.2; P = 0.007, one-tailed U test) in corneal staining, but only compared with no treatment and only on the final day (day 8) of treatment (Fig. 4A) . In contrast, 93:60 achieved significance on all evaluation days compared with no treatment (2.9-to 3.2-point reduction in mean staining score; P < 0.0001 for all, one-tailed U test), PBS (2.0-to 2.5-point reduction; P = 0.0001-0.002), or anakinra (1.7-to 1.8-point reduction; P = 0.002-0.007) (Fig. 4A) . Furthermore, 93:60 was active at concentrations as low as 0.1 mg/mL (significant reduction in mean staining score on days 6 and 8 of therapy; P = 0.009 and 0.008, respectively, one-tailed U test), but not consistently (Fig. 4B) . This finding suggests that in this model, 93:60 may be ∼100 times more effective than anakinra. Cyclosporin A (as Restasis) was ineffective in this model (P = 0.56-0.97 vs. no treatment on any treatment day, two-tailed U test) (Fig. 4C ).
Discussion
We have taken a unique, rational approach to creating an improved cytokine ligand by combining features of existing ligands through chimerization. Our primary goal was to increase antagonist potency, and then to select from among a series for the molecule with the best drug-like properties. Generally, the chimeras were well behaved and more potent than the parent molecules ( Figs. 1 and 2) . One antagonist in particular, 93:60, bound IL-1R1 85-fold more tightly than IL-1Ra (Table 1 ). In IL-1 signaling, the receptor is internalized on IL-1α, but not IL-1Ra, binding (32) . Thus, the stability of the 93:60/IL-1R1 complex in the presence of competitor (dissociation t 1/2 of 31 h) suggests that this complex will turn over only with IL-1R1 turnover (t 1/2 of 11 h in EL4 T cells) 
IL-1β 1.5 × 10 (33). This increased efficiency of blockade translated to the in vivo setting; 93:60 was ∼100-fold more potent than anakinra in reducing corneal staining in a therapeutic rodent model of DED (Fig. 4) . In addition to the higher potency obtained by chimerism, these engineered proteins demonstrated substantially improved thermal stability (6-9°C in the case of 93:60) compared with parent molecules (Fig. 3) . Thus, IL-1β and IL-1Ra both appear to have discrete, thermally stable cores, although located at opposite ends of the fold. The idea of regional "nuclei" of thermal stability within the β-trefoil fold is not anticipated by prior studies (34) (35) (36) . Analysis of residue-specific thermal denaturation of IL-1β revealed only context-dependent, not regional, rates of unfolding (37) . Molecular dynamics simulation of WT and substitution mutants of IL-1β has suggested that residues in site B, present in all our chimeras, drive topological frustration in IL-1β folding and slow the acquisition of the native state at a fixed temperature (36, 38) .
Some insights into the relationship between acute and longterm thermal stability have been obtained for the β-trefoil fold. Although IL-1Ra melts at 56-62.5°C (Fig. 3A) (34, 39) , nearnative, partially unfolded states below this temperature can trigger aggregation. Concentrated (100 mg/mL) IL-1Ra aggregates at 40°C within 2 h, near the T onset of 38°C, (Fig. 3A) , whereas lower concentrations (12-27 mg/mL) aggregate after ∼1 d at 47°C. IL-1β aggregates at 39°C, above the T onset of 34°C, but not at 30°C (40) . Thus, T onset may be more relevant to long-term thermal stability than T m . All of the chimeras in this study exhibited increased T m and T onset (Fig. 3B) , suggesting that they will also have enhanced long-term thermal stability compared with the parent molecules.
Along with their increased T onset , the chimeras lack three lysines in IL-1Ra (K6, K93, and K96) that form a positively charged cluster on the surface and drive the earliest steps in aggregation (39) . This may further enhance both aggregation stability and solubility. Collectively, these data suggest that some of these chimeras may be particularly stable, suggesting their suitability for eye-drop formulation.
Direct measurement of the affinity of IL-1β and IL-1Ra to IL-1R1 fragments shows a much higher affinity of both ligands for the D1-D2 receptor fragment (bearing site A) than for D3 (bearing site B) (Table S1 ) (23) . In their relative IL-1R1 and IL-1R2 binding affinities, the chimeras (agonist and antagonist) all behave like IL-1Ra, not like IL-1β ( Table 2 ), showing that the site A interaction is the driver of affinity not only for IL-1R1, but also for IL-1R2. Thus, site A of IL-1R2 is optimized for IL-1β, whereas site A of IL-1R1 is optimized for IL-1Ra. The >80-fold greater selectivity of the IL-1R2 decoy receptor for IL-1β over IL-1Ra ( Table 2 ) is one of the natural regulatory mechanisms in the IL-1 system (5), and preservation of the lower IL-1R2 affinity in 93:60 (>20-fold lower than IL-1β) suggests that IL-1β will still outcompete it for binding in the presence of physiological levels of 93:60. Thus, the agonist 121:30, which is more potent than IL-1β in some assays (Fig. 1) , may be an even more potent agonist in a physiological system, given that it will escape IL-1R2 regulation.
Until the appearance of the ternary complex structure, site B was considered related to the agonistic properties of IL-1β (41) . The ternary complex structure reveals no particular role for site B, except perhaps to coordinate the D1, D2, and D3 IL-1R1 subdomains, which appear capable of free rotation around the flexible hinge that connects them (25, 26, 42) . The chimeras described here demonstrate that site B is insufficient for agonism and that its absence is not necessary for antagonism, leaving open the question of its role in IL-1β (or the reason for its absence in IL-1Ra).
Numerous previous studies have attempted to define the residues in IL-1β and IL-1Ra that determine agonism vs. antagonism; based on mutational and crystal structure analyses, a site centered on D145 of IL-1β appears to be key (25) (26) (27) . Nonetheless, conversion of IL-1β to a complete antagonist or of IL-1Ra to a full agonist has not been achieved to date. Analysis has been hampered by the low overall sequence identity (25%), despite a similar fold and similar geometry of IL-1R1 interaction. The chimeras 121:30 and 93:60 are a pair of fully (even super) active agonist/antagonist ligands that differ in just 23 positions, suggesting that these differences are key (Fig. S5) . Of the residues in IL-1β that make contact with IL-1RAcP in the ternary complex (25) , only six (KGGQ/138-141, I143, and D145) are common to the 121:30/93:60 differences, suggesting that these may be the most important residues.
In summary, we have rationally designed a receptor antagonist that is more potent and stable than IL-1Ra. Our chimera 93:60 meets the design criteria for an agent optimized for topical treatment of DED, for which it is currently under development (as EBI-005). .
Methods
Expression and Purification of Proteins. Inserts encoding His-tagged or untagged versions of the ligands were synthesized, cloned into E. coli expression vector pET28a(+) (Millipore), and expressed in BL21 (New England Biolabs) or BLR(DE3) cells (Millipore) after induction with 1 mM isopropyl-β-D-1-thiogalactopyranoside. His-tagged proteins were purified from the soluble fraction of an E. coli lysate (grown in a shake flask) using nickelaffinity chromatography (Life Technologies). Untagged 93:60 for crystallography and in vivo studies was purified from the soluble fraction of an E. coli lysate (grown in a fed-batch bioreactor) using a combination of cationand anion-exchange chromatography, then concentrated to 50 mg/mL, and the buffer was exchanged into 1.25× PBS. The final material was >99% pure and >98% monomer (Fig. S6 ) and contained <5 EU/mL of endotoxin.
Cell-Based Assays. IL-1β reporter assays. In agonist mode, HEK-blue IL-1β cells (InvivoGen) were incubated with ligands at various concentrations for 24 h. In antagonist mode, cells were stimulated with 6 pM human IL-1β (R&D Systems) and coincubated with ligands at various concentrations for 24 h. The conditioned media were then collected and assayed for alkaline phosphatase activities by adding QUANTI-Blue (InvivoGen) substrate and reading the A 650 . IL-6 production assay. In agonist mode, human osteosarcoma MG-63 cells (American Type Culture Collection) were incubated with ligands at various concentrations for 24 h. In antagonist mode, cells were stimulated with various concentrations of ligands in the presence of 11 pM human IL-1β (R&D Systems) for 24 h. IL-6 production from the cells was then quantitated with a human IL-6 ELISA kit (R&D Systems) with reference to a standard curve. Proliferation Assay. In agonist mode, 1 × 10 5 D10.G4.1 cells/mL (American Type Culture Collection) were incubated with ligands at various concentrations for 48 h. In antagonist mode, 1 × 10 5 cells/mL were incubated with various concentrations of ligands in the presence of 6 pM IL-1β for 48 h. Viable cells were quantitated by resazurin conversion (R&D Systems) and measurement of the emission at 590 nM on excitiation at 544 nM.
In Vitro Binding Affinities. IL-1R1 or IL-1R2 extracellular domains (R&D Systems) were immobilized on a 500-kDa carboxymethyl dextran chip (Reichert) via standard amine coupling. Then 6xHis-tagged ligands in PBS with 0.005% Tween-20 were flowed over the chip at a flow rate of 50 μL/min at 25°C, and data were collected and analyzed with an SPR Spectrometer (Reichert 7000DC). Sensorgrams were analyzed using the provided software to calculate k a , k d , and K D values. Fitted k d values below 5 × 10 −5 are given as <5 × 10 −5 owing to the inaccuracy of the fit at these values. All SPR measurements were performed in duplicate. For competition studies, IL-1R1 was immobilized on an ELISA plate, and 93:60 (6xHis-tagged) or IL-1Ra (6xHis-tagged) were allowed to bind. Various concentrations of untagged 93:60 were added to the plate, which was then incubated for 16 h at 25°C, and the remaining His-tagged protein bound was detected by an HRP-conjugated anti-His antibody (Abcam). To derive the k a value from the fraction dissociated, we assumed exponential decay and used the formula k a = −ln f/t, where f is the fraction remaining and t is the incubation time (16 h). The fraction remaining (70% for 93:60 and 18% for IL-1Ra) was taken as the average of the three highest competitor concentration values, at which saturation was achieved. The half-life of the complex is given by 0.693/k a .
Differential Scanning Fluorimetry. Measurements were conducted on a BioRad CFX96 real-time PCR system using 12.5 μg of protein in 25 μL of PBS (pH 7.4) supplemented with SYPRO orange dye (Invitrogen) at a final concentration of 5× . Samples were heated from 4°C to 95°C at a rate of 0.5°C/10 s. Experiments were run in duplicate, and fluorescence intensities were plotted as a function of temperature.
Crystallization and Structure Determination. For 93:60 crystallization, a final gel filtration step was carried out using a Superdex S75 column (GE Healthcare) equilibrated in 20 mM Hepes (pH 7.5) and 50 mM NaCl. The binary complex was formed by mixing a molar excess of 93:60 with IL-1R1, purified as described previously (25) integrated, and scaled with the HKL package (43) . Structures were solved by molecular replacement using the Phaser program (44 In Vivo Studies. C57/BL6 female mice (Jackson Laboratory) were allowed to acclimate for at least 1 wk. Mice were assessed for baseline level of corneal fluorescein staining on day 0 using 0.4 μL of 1% fluorescein solution. Scoring (National Eye Institute grading scale, range 0-15) was done by two observers using a fluorescent stereomicroscope with a teaching bridge at ∼8-11 min after fluorescein administration. Mice with a score of ≤7 in both eyes were used.
On day 1, mice were placed in a custom-built controlled environment chamber set to ∼20% relative humidity and an airflow rate of ∼21 L/min/cage. No pharmacologic dessicants (e.g., atropine, scopolamine) were used. On day 3, mice were scored again and randomized into treatment groups. Purified untagged 93:60 at 50 mg/mL was diluted to 10, 1, or 0.1 mg/mL in 1× PBS; 147 mg/mL anakinra (Kineret; Swedish Orphan Biovitrum) was diluted to 10 mg/mL with 1× PBS; and 0.5 mg/mL cyclosporine A (Restasis; Allergan) was used undiluted. Controls were 1× PBS or no treatment. Starting on day 3, 3 μL of solution was applied to each eye twice daily for 8 d. Treatment groups were masked, and scores were assessed on days 7, 9, and 11.
Statistical Analysis. The fluorescein staining score produces an integer value of 0-15 for each eye evaluated. Differences between groups were compared used the Mann-Whitney U test, one-or two-tailed as specified, with α = 0.05. Comparisons were made within a given treatment day, not across days, and were not corrected for multiple testing (6, 10, and 3 pairwise tests for each day for the data shown in Fig. 4 A, B , and C, respectively).
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